Gapping up
In reaction to earnings/guidance:
- DNMR +1.9% (guidance), FL +1.2%
Other news:
- NYCB +30.7% (acquires certain assets and assumes certain liabilities of Signature Bridge Bank From the FDIC)
- KRTX +14.5% (results from phase 3 emergent-3 Trial of KarXT in schizophrenia)
- PACW +13.9% (provides end of end of week update)
- ARQT +3.3% (Presents Late-Breaking Data from the INTEGUMENT Phase 3 Trials in Atopic Dermatitis at American Academy of Dermatology Annual Meeting)
- ABR +3.1% (approves share repurchase authorization up to $50 mln)
- ARWR +2.9% (announces the U.S. FDA has granted Fast Track designation to ARO-APOC3 for reducing triglycerides in adult patients with familial chylomicronemia syndrome)
- EVEX +2.8% (to delay 10-K filing)
- BANF +2.8% (postive Barron's article)
- DYN +2% (Announces Presentations on its DM1 and DMD Programs at the 2023 Muscular Dystrophy Association Clinical & Scientific Conference)
- TALO +1.8% (announces $100 million share repurchase authorization)
- FYBR +1.2% (Ares Mgmt discloses 250000 share purchase on Mar 15 and 81208 share purchase on Mar 16)
- EXEL +1.1% (authorized the repurchase of up to $550 mln of the company's common stock before the end of 2023)
- EFXT +1% (provides succession plan for CFO)
- AG +1% (renews share repurchase program)
Analyst comments:
- ASPN +5.7% (upgraded to Buy from Hold at The Benchmark Company)
- BN +0.9% (upgraded to Outperform from Neutral at Credit Suisse)
- META +0.5% (upgraded to Buy from Hold at Edward Jones)